Bioengineered bugs, drugs and contentious issues in patenting

References

• Fialho AM, Chakrabarty AM. Fialho AM, Chakrabarty AM. The role and importance of intellectual property generation and protection in drug development. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools 2009; Nutley N.J. John Wiley
   Google Scholar
• Fialho AM, Chakrabarty AM. Fialho AM, Chakrabarty AM. Promiscuous anticancer drugs from pathogenic bacteria: rational versus intelligent drug design. Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools 2009; Nutley N.J. John Wiley
   Google Scholar
• Chakrabarty AM, Ornston LN, Sligar S. Plasmids and nutritional diversity. Experiences in Biochemical Perception 1982; New York, NY Academic Press 111 - 120
   Google Scholar
• Chakrabarty AM. Plasmids in Pseudomonas. Annu Rev Genet 1976; 10:7 - 30
   PubMed Web of Science ®Google Scholar
• Ghosal D, You IS, Chatterjee DK, Chakrabarty AM. Microbial degradation of halogenated compounds. Science 1985; 228:135 - 141
   PubMed Web of Science ®Google Scholar
• Chakrabarty AM. Microbial degradation of toxic chemicals: evolutionary insights and practical considerations. ASM News 1996; 62:130 - 137
   Google Scholar
• Friello DA, Mylroie JR, Chakrabarty AM. Sharpley JM. Use of genetically-engineered multi-plasmid microorganisms for rapid degradation of fuel hydrocarbons. Proceedings of 3rd International Biodegradation Symposium 1976; Essex, England Applied Science Publications 205 - 214
   Google Scholar
• Kevles DJ. Ananda Chakrabarty wins a patent: biotechnology, law and society, 1972–1980. Historical Studies in the Physical and Biological Sciences (HSPS) 1994; 25:111 - 135
   PubMedGoogle Scholar
• Chakrabarty AM. Chisum DS, Nard CA, Schwartz HF, Newman P, Kieff FS. Diamond v. Chakrabarty: a historical perspective. Principles of Patent Law 1998; New York, NY Foundation Press 783 - 788
   Google Scholar
• Chakrabarty AM. Atlas RM. Moving ahead with pseudomonad genes. Many Faces Many Microbes 2000; Washington, DC ASM Press 235 - 242
   Google Scholar
• Chakrabarty AM. Magnus D, Caplan A, McGee G. Patenting of life forms: from a concept to reality. Who Owns Life? 2002; Amherst, NY Prometheus Books 17 - 24
   Google Scholar
• Chakrabarty AM. Kieff FS. Patenting life forms: yesterday, today and tomorrow. Perspectives on Properties of the Human Genome Project 2003; San Diego, CA Elsevier Academic Press 3 - 11
   Google Scholar
• Chakrabarty AM. Santosuosso A, Gennari G, Garagna S, Zuccotti M, Redi CA, et al. Genomics, law and justice. Science, Law and the Courts in Europe 2004; Pavia, Italy Ibis 145 - 151
   Google Scholar
• Fialho AM, Stevens FJ, Das Gupta TK, Chakrabarty AM. Beyond host-pathogen interactions: microbial defense strategy in the host environment. Curr Opin Biotechnol 2007; 18:279 - 286
   PubMed Web of Science ®Google Scholar
• Fialho AM, Das Gupta TK, Chakrabarty AM. Designing promiscuous drugs? Look at what nature made!. Lett Drug Design Discov 2007; 4:40 - 43
   Web of Science ®Google Scholar
• Mahfouz M, Hashimoto W, Das Gupta TK, Chakrabarty AM. Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy. Plasmid 2007; 57:4 - 17
   PubMed Web of Science ®Google Scholar
• Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, et al. Bacterial redox protein azurin, tumor suppressor protein p53 and regression of cancer. Proc Natl Acad Sci USA 2002; 99:14098 - 14103
   PubMed Web of Science ®Google Scholar
• Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004; 23:2367 - 2378
   PubMed Web of Science ®Google Scholar
• Hong CS, Yamada T, Hashimoto W, Fialho AM, Das Gupta TK, Chakrabarty AM. Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein. Cell Cycle 2006; 5:1633 - 1641
   PubMed Web of Science ®Google Scholar
• Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation and inhibition of cancer growth. Biochemistry 2007; 46:1799 - 1810
   PubMed Web of Science ®Google Scholar
• Das Gupta TK, Chakrabarty AM. Compositions and methods to prevent cancer with cupredoxins US patent US2008/0139471 published June 12, 2008
   Google Scholar
• Chaudhari A, Fialho AM, Ratner D, Gupta P, Hong CS, Kahali S, et al. Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by azurin. Cell Cycle 2006; 5:1642 - 1648
   PubMed Web of Science ®Google Scholar
• Naguleswaran A, Fialho AM, Chaudhari A, Hong CS, Chakrabarty AM, Sullivan WJ Jr. Azurin-like protein blocks invasion of Toxoplasma gondii through potential interactions with parasite surface antigen SAG1. Antimicrob Agents Chemotherap 2008; 52:402 - 408
   PubMed Web of Science ®Google Scholar
• Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res 2009; 69:537 - 546
   PubMed Web of Science ®Google Scholar
• Mehta RR, Taylor BN, Yamada T, Beattie CW, Das Gupta TK, Chakrabarty AM. Compositions and methods to control angiogenesis with cupredoxins US patent No. 7,556,810 issued on July 7, 2009
   Google Scholar
• Kwan J, Fialho AM, Kundu M, Thomas J, Hong CS, Das Gupta TK, Chakrabarty AM. Bacterial proteins as potential drugs in the treatment of leukemia. Leuk Res 2009; 33:1392 - 1399
   PubMed Web of Science ®Google Scholar
• Kundu M, Thomas J, Fialho AM, Kwan JM, Moreira L, Mahfouz M, et al. The anticancer activity of the N-terminal CARD-like domain of arginine deiminase (ADI) from Pseudomonas aeruginosa. Lett Drug Design Discov 2009; 6:403 - 412
   Web of Science ®Google Scholar